Table 5 Comparison of ocular surface parameters in the two groups at each timepoint of the study

BUT

baseline

4 m

8 m

12 m

18 m

Cit-B12

10.1 ± 5.7

9.0 ± 5.9

9.7 ± 7.2

9.6 ± 4.7

9.8 ± 6.3

Placebo

8.6 ± 5.5

7.8 ± 5.0

7.4 ± 6.3

10.9 ± 6.5

9.4 ± 5.5

p

0.48

0.56

0.39

0.62

0.87

SCHIRMER

baseline

4 m

8 m

12 m

18 m

Cit-B12

15.9 ± 8.9

14.8 ± 7.1

14.7 ± 7.7

16.5 ± 9.0

14.4 ± 9.2

Placebo

14.1 ± 8.8

14.8 ± 9.2

15.5 ± 7.6

17.5 ± 11.1

16.4 ± 11.0

p

0.59

0.99

0.80

0.83

0.66

baseline

4 m

8 m

12 m

18 m

Cit-B12

1.40 ± 0.60

1.60 ± 0.50

1.21 ± 0.42

1.11 ± 0.32

1.00 ± 0.47

Placebo

1.40 ± 0.70

1.40 ± 0.70

1.10 ± 0.57

1.13 ± 0.35

1.25 ± 0.46

p

0.99

0.43

0.60

0.89

0.22

baseline

4 m

8 m

12 m

18 m

Cit-B12

0.20 ± 0.41

0.40 ± 0.50

0.21 ± 0.42

0.05 ± 0.23

0.11 ± 0.32

Placebo

0.30 ± 0.48

0.20 ± 0.42

0.10 ± 0.32

0.01 ± 0.00

0.13 ± 0.35

p

0.58

0.26

0.43

0.33

0.89

OSDI

baseline

4 m

8 m

12 m

18 m

Cit-B12

9 ± 7

8 ± 7

7 ± 7

6 ± 5

8 ± 10

Placebo

13 ± 11

8 ± 6

7 ± 5

9 ± 7

8 ± 8

p

0.30

0.90

0.90

0.21

0.98